000 | 01913 a2200553 4500 | ||
---|---|---|---|
005 | 20250515044431.0 | ||
264 | 0 | _c20070405 | |
008 | 200704s 0 0 eng d | ||
022 | _a1523-1747 | ||
024 | 7 |
_a10.1038/sj.jid.5700603 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aTanaka, Akane | |
245 | 0 | 0 |
_aTopical application with a new NF-kappaB inhibitor improves atopic dermatitis in NC/NgaTnd mice. _h[electronic resource] |
260 |
_bThe Journal of investigative dermatology _cApr 2007 |
||
300 |
_a855-63 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdministration, Topical |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aB-Lymphocytes _xmetabolism |
650 | 0 | 4 |
_aBenzamides _xadministration & dosage |
650 | 0 | 4 | _aCell Lineage |
650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
650 | 0 | 4 | _aCells, Cultured |
650 | 0 | 4 |
_aDermatitis, Atopic _xpathology |
650 | 0 | 4 | _aDown-Regulation |
650 | 0 | 4 | _aImmunocompetence |
650 | 0 | 4 |
_aImmunoglobulin E _xbiosynthesis |
650 | 0 | 4 |
_aImmunosuppressive Agents _xpharmacology |
650 | 0 | 4 |
_aKeratinocytes _xpathology |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aMast Cells _xdrug effects |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aMice, Inbred Strains |
650 | 0 | 4 |
_aNF-kappa B _xantagonists & inhibitors |
650 | 0 | 4 |
_aNeurites _xdrug effects |
650 | 0 | 4 | _aOintments |
650 | 0 | 4 | _aSeverity of Illness Index |
650 | 0 | 4 |
_aSkin _xdrug effects |
650 | 0 | 4 | _aSpleen |
650 | 0 | 4 |
_aTacrolimus _xpharmacology |
650 | 0 | 4 |
_aTh2 Cells _xmetabolism |
650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xmetabolism |
700 | 1 | _aMuto, Susumu | |
700 | 1 | _aJung, Kyungsook | |
700 | 1 | _aItai, Akiko | |
700 | 1 | _aMatsuda, Hiroshi | |
773 | 0 |
_tThe Journal of investigative dermatology _gvol. 127 _gno. 4 _gp. 855-63 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.jid.5700603 _zAvailable from publisher's website |
999 |
_c16642981 _d16642981 |